Company registration number 04469533 (England and Wales)
SPEEDS PHARMACY LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2025
PAGES FOR FILING WITH REGISTRAR
SPEEDS PHARMACY LTD
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
SPEEDS PHARMACY LTD
BALANCE SHEET
AS AT
30 SEPTEMBER 2025
30 September 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
4
-
0
-
0
Tangible assets
5
461,756
272,228
Current assets
Stocks
96,767
93,672
Debtors
6
518,126
538,858
Cash at bank and in hand
549,828
715,867
1,164,721
1,348,397
Creditors: amounts falling due within one year
7
(387,245)
(588,059)
Net current assets
777,476
760,338
Total assets less current liabilities
1,239,232
1,032,566
Provisions for liabilities
(93,780)
(56,730)
Net assets
1,145,452
975,836
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
1,145,352
975,736
Total equity
1,145,452
975,836
SPEEDS PHARMACY LTD
BALANCE SHEET (CONTINUED)
AS AT
30 SEPTEMBER 2025
30 September 2025
- 2 -

For the financial year ended 30 September 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 18 March 2026 and are signed on its behalf by:
Mr D Speed
Director
Company registration number 04469533 (England and Wales)
SPEEDS PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 3 -
1
Accounting policies
Company information

Speeds Pharmacy Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 7 The Square, Mynydd Isa, Near Mold, Flintshire, CH7 6UY.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Turnover

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that are recover able.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold land and buildings
Plant and equipment
15% on NBV
Fixtures and fittings
15% - 25% on NBV
Computers
25% on cost
Motor vehicles
25% on NBV
SPEEDS PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 4 -

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.5
Cash at bank and in hand

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.6
Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Changes in the fair value of derivatives that are designated and qualify as fair value hedges are recognised in profit or loss immediately, together with any changes in the fair value of the hedged asset or liability that are attributable to the hedged risk.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

SPEEDS PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 5 -
1.8
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
27
26
4
Intangible fixed assets
Goodwill
£
Cost
At 1 October 2024 and 30 September 2025
525,000
Amortisation and impairment
At 1 October 2024 and 30 September 2025
525,000
Carrying amount
At 30 September 2025
-
0
At 30 September 2024
-
0
SPEEDS PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 6 -
5
Tangible fixed assets
Leasehold land and buildings
Plant and equipment
Fixtures and fittings
Computers
Motor vehicles
Total
£
£
£
£
£
£
Cost
At 1 October 2024
61,595
254,788
159,192
94,791
13,460
583,826
Additions
41,325
55,541
95,137
32,579
20,626
245,208
Disposals
-
0
-
0
(135,547)
(51,822)
(13,460)
(200,829)
At 30 September 2025
102,920
310,329
118,782
75,548
20,626
628,205
Depreciation and impairment
At 1 October 2024
16,285
56,658
150,451
77,937
10,267
311,598
Depreciation charged in the year
-
0
33,920
8,152
8,243
1,289
51,604
Eliminated in respect of disposals
-
0
-
0
(134,832)
(51,654)
(10,267)
(196,753)
At 30 September 2025
16,285
90,578
23,771
34,526
1,289
166,449
Carrying amount
At 30 September 2025
86,635
219,751
95,011
41,022
19,337
461,756
At 30 September 2024
45,310
198,130
8,741
16,854
3,193
272,228
6
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
487,155
480,664
Other debtors
27,961
55,184
Prepayments and accrued income
3,010
3,010
518,126
538,858
7
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
350,692
522,443
Corporation tax
18,527
15,828
Other taxation and social security
13,378
10,852
Other creditors
1,648
35,936
Accruals and deferred income
3,000
3,000
387,245
588,059
SPEEDS PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 7 -
8
Directors' transactions

Included in other debtors was a loan to Mr and Mrs D J Speed, who is a director and shareholder of the company. The outstanding balance at the year end was £1,648 (2024: £1,336).

Dividends totalling £0 (2024 - £0) were paid in the year in respect of shares held by the company's directors.

2025-09-30 2024-10-01 false false false 18 March 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Mr D Speed Mrs C Speed Mr J D Speed Mrs C Speed 04469533 2024-10-01 2025-09-30 04469533 2025-09-30 04469533 2024-09-30 04469533 core:Goodwill 2025-09-30 04469533 core:Goodwill 2024-09-30 04469533 core:PlantMachinery 2025-09-30 04469533 core:FurnitureFittings 2025-09-30 04469533 core:ComputerEquipment 2025-09-30 04469533 core:MotorVehicles 2025-09-30 04469533 core:LandBuildings 2024-09-30 04469533 core:PlantMachinery 2024-09-30 04469533 core:FurnitureFittings 2024-09-30 04469533 core:ComputerEquipment 2024-09-30 04469533 core:MotorVehicles 2024-09-30 04469533 core:CurrentFinancialInstruments core:WithinOneYear 2025-09-30 04469533 core:CurrentFinancialInstruments core:WithinOneYear 2024-09-30 04469533 core:ShareCapital 2025-09-30 04469533 core:ShareCapital 2024-09-30 04469533 core:RetainedEarningsAccumulatedLosses 2025-09-30 04469533 core:RetainedEarningsAccumulatedLosses 2024-09-30 04469533 bus:Director1 2024-10-01 2025-09-30 04469533 core:PlantMachinery 2024-10-01 2025-09-30 04469533 core:FurnitureFittings 2024-10-01 2025-09-30 04469533 core:ComputerEquipment 2024-10-01 2025-09-30 04469533 core:MotorVehicles 2024-10-01 2025-09-30 04469533 2023-10-01 2024-09-30 04469533 core:Goodwill 2024-09-30 04469533 core:LandBuildings core:LeasedAssetsHeldAsLessee 2024-09-30 04469533 core:PlantMachinery 2024-09-30 04469533 core:FurnitureFittings 2024-09-30 04469533 core:ComputerEquipment 2024-09-30 04469533 core:MotorVehicles 2024-09-30 04469533 2024-09-30 04469533 core:LandBuildings core:LeasedAssetsHeldAsLessee 2025-09-30 04469533 core:LandBuildings core:LeasedAssetsHeldAsLessee 2024-10-01 2025-09-30 04469533 core:CurrentFinancialInstruments 2025-09-30 04469533 core:CurrentFinancialInstruments 2024-09-30 04469533 bus:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 04469533 bus:SmallCompaniesRegimeForAccounts 2024-10-01 2025-09-30 04469533 bus:FRS102 2024-10-01 2025-09-30 04469533 bus:AuditExemptWithAccountantsReport 2024-10-01 2025-09-30 04469533 bus:Director2 2024-10-01 2025-09-30 04469533 bus:Director3 2024-10-01 2025-09-30 04469533 bus:CompanySecretary1 2024-10-01 2025-09-30 04469533 bus:FullAccounts 2024-10-01 2025-09-30 xbrli:pure xbrli:shares iso4217:GBP